TABLE 2.

Pharmacokinetic parameters of fosfomycin in plasma after intravenous and oral administration

Fosfomycin treatmenta (no. of subjects)	Value (means ± SD) for:
	Cmax (μg/ml)	Tmax (h)	AUClast (μg · h/ml)	AUC0–∞ (μg · h/ml)	V or V/F (liters)	CL or CL/F (liters/h)	CLR (liters/h)	t1/2 (h)
1 g i.v. (n = 27)	44.3 ± 7.6	1.1 ± 0.05	117 ± 27.7	120 ± 28.5	29.7 ± 5.7	8.7 ± 1.7	6.6 ± 1.9	2.4 ± 0.4
8 g i.v. (n = 27)	370 ± 61.9	1.08 ± 0.01	1,056 ± 192	1,060 ± 192	31.5 ± 10.4	7.8 ± 1.4	6.3 ± 1.6	2.8 ± 0.6
3 g p.o. (n = 28)	26.8 ± 6.4	2.25 ± 0.4	178 ± 49.9b	191 ± 57.6	204 ± 70.7g	17.0 ± 4.7h	6.5 ± 1.8	9.04 ± 4.5
	26.8 ± 6.4	2.25 ± 0.4	174 ± 45.1c	187 ± 52.2	184 ± 65.6g	17.2 ± 4.6h	6.3 ± 1.7	7.93 ± 3.5
	26.8 ± 6.4	2.25 ± 0.4	165 ± 39.2d	179 ± 43.8	152 ± 53.5g	17.8 ± 4.4h	6.1 ± 1.7	6.09 ± 2.1
	26.8 ± 6.4	2.25 ± 0.4	156 ± 36.6e	174 ± 40.1	134 ± 54.9g	18.2 ± 4.2h	NRi	5.17 ± 2.1
	26.8 ± 6.4	2.25 ± 0.4	139 ± 33.6f	160 ± 37.4	109 ± 54.1g	19.7 ± 4.6h	6.0 ± 1.7	3.91 ± 2.1

^aEach subject received only one dose of fosfomycin. Pharmacokinetic parameters are displayed for incremental noncompartmental analyses on partial areas from 0 to 12, 0 to 24, 0 to 36, and 0 to 48 h, as delineated.

^bAUC_0–48.

^cAUC_0–36.

^dAUC_0–24.

^eAUC_0–18.

^fAUC_0–12.

^gV/F.

^hCL/F.

ⁱCL_R not reported given the lack of corresponding urine collection interval.